GHK-Cu: What the Evidence Shows for Skin, Hair and Injections

GHK-Cu is a copper-carrying fragment of a protein found in human blood, and the evidence for it depends almost entirely on how it is used. Applied to the skin, it has a thin human record: a handful of small studies, two of the three published randomized trials negative on their objective measures, and the most-quoted wrinkle results coming from 2002 conference presentations rather than journal papers.^[10][12][9] Injected, it has essentially no human record at all. FDA has drawn the same line: since May 2026, compounding pharmacies get enforcement leeway for GHK-Cu by every route except injection.^[1]

What GHK-Cu is

GHK stands for glycine-histidine-lysine, three amino acids. Loren Pickart reported in 1973 that a small factor in human blood kept liver cells alive longer in culture; by 1977 it had been identified as this tripeptide.^[6][7] In 1980 his group showed that it grabs copper tightly and helps carry the metal into cells, which is where the “-Cu” comes from.^[8] The copper complex has an official drug name, prezatide copper, and on cosmetic labels it usually appears as copper tripeptide-1.^[24]

Much of the popular case for GHK-Cu rests on one observation: blood levels fall with age, from about 200 ng/mL at 20 to about 80 ng/mL by 60, according to a 2018 review.^[9] That is a correlation, not proof that topping it up does anything. It is also worth knowing who has made the case. The broadest claims, from collagen and wound repair to gene-expression “resetting,” trace largely to reviews by Pickart and colleagues, whose papers list their affiliation as Skin Biology in Bellevue, Washington.^[9] Other reviews published in 2025 and 2026 are much more cautious.^[13][18]

The GHK-Cu evidence in people, study by study

Skin and wrinkles: the most-sold use, with the thinnest papers

Copper peptide serums are sold mainly for wrinkles, firmness and “skin repair.” The studies most often quoted for those claims describe a 12-week facial cream study in 71 women and an eye cream study in 41 women, both reporting firmer, denser skin with fewer fine lines. In the 2018 review that cites them, both trace to presentations at the American Academy of Dermatology’s 2002 annual meeting.^[9] Meeting presentations are not peer-reviewed in the way a journal paper is, and they do not publish enough detail to check how the comparisons were run.

The one randomized skin trial in a journal points the other way. After laser resurfacing around the mouth, 13 patients used skin care with or without GHK-Cu. Blinded evaluators and computer analysis found no difference in redness, wrinkles or overall skin quality; the only difference was that patients using GHK-Cu were more satisfied with their skin.^[12] A 2025 review of GHK as an anti-wrinkle ingredient, whose authors declared no conflicts of interest, put it plainly: despite wide use in products, there is “a surprising absence of clinical studies.”^[13]

There is also a delivery problem. GHK-Cu dissolves easily in water, which makes it hard to push through the outer layer of skin. In a lab test on donated human skin, almost no peptide or copper crossed intact skin over nine hours; it got through only after the skin had been punctured with microneedles.^[14] That does not prove a serum does nothing, but it does mean the formulation matters as much as the label.

Wound healing: one positive trial, one negative

Wounds are where GHK-Cu came closest to becoming a medicine. A 1992 trial in 86 people with venous leg ulcers found a 0.4% copper tripeptide cream did no better than an inert placebo cream.^[10] A 1994 multicenter trial in diabetic foot ulcers was positive: alongside a strict wound-care routine, GHK-Cu gel closed a median 98.5% of wound area against 60.8% with the vehicle gel, and infections were less common.^[11]

Neither result was followed by an approved drug, and three decades later the question is open again. A randomized, double-blind phase 2 trial of a GHK-Cu gel on small, standardized skin wounds in healthy adults began enrolling in February 2026, with about 60 participants planned and results not expected before 2027.^[20] A 2026 systematic review called the clinical evidence “sparse” and concluded GHK-Cu “should be regarded as a promising but unproven” treatment.^[18] Another 2026 review of aesthetic uses found 20 studies, of which only 2 were randomized trials.^[19]

Hair growth: the studies are mostly of something else

Hair is the claim that matters most to people on GLP-1 drugs, and it is the weakest. The lab study most often cited for “copper peptides grow hair” tested AHK-Cu, a related copper peptide with alanine in place of glycine, on hair follicles in a dish. It lengthened follicles there, but it was not GHK-Cu and it was not in a person.^[15] The one placebo-controlled human hair trial used GHK bound to 5-aminolevulinic acid, with no copper: men using it had more hairs counted after six months, but no thicker or longer hair.^[16] A 2024 scalp study that reported higher hair density used a serum with several other active ingredients, ran 15 days, had no comparison group, and included an author employed by the product’s maker.^[17]

So there is no trial showing that GHK-Cu itself regrows human scalp hair. There is also a legal point here. Under FDA rules, a product sold with a claim that it will “restore hair growth” is a drug, whatever it calls itself, because the intended use is to change how the body works.^[25] So a copper peptide serum marketed as a cosmetic is not, legally, promising regrowth.

Injected GHK-Cu: no human trials, and FDA’s specific worry

Injectable GHK-Cu turns up on telehealth peptide menus, but none of the human studies in the table above injected it. A 2026 review of injectable peptides for sports medicine physicians found GHK-Cu “showed promise” in wound healing, but that no clinical data support using it for musculoskeletal conditions, and that dosing, frequency and duration “remains unknown.”^[21] Any dose on a vial label or a forum is therefore a guess built from animal work.

When FDA set out the risk it sees, it was specific to the injection:^[3]

“Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”^[3]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

Immunogenicity means the immune system reacting to the product, for example by making antibodies against it. Clumping of peptide molecules and leftover fragments from manufacturing make that more likely, and they are exactly the quality problems that are hardest to see in a vial. A topical product sitting on intact skin, which barely lets the peptide through, does not raise the same concern.^[14]

The copper question

Copper makes up about 16% of the weight of the GHK-Cu complex, so each milligram carries roughly 0.16 mg of copper.^[24] Copper is an essential nutrient. What changes with an injection is the route. The gut is the body’s main regulator of how much copper it takes in, and an injection goes around it.^[22] In excess, free copper damages cells.^[22] Nobody has measured what repeated GHK-Cu injections do to copper levels or how much copper comes loose from the peptide once it is in the blood, a gap a 2026 review flagged for formulations generally.^[18]

One group should not experiment at all: people with Wilson disease, an inherited disorder in which the body cannot clear copper and it builds up in the liver and brain.^[23] Anyone who has been told they have a copper-handling problem, or who has unexplained liver test abnormalities, should raise GHK-Cu with a doctor before using any form.

GHK-Cu’s legal status, October 2026

GHK-Cu is not an approved drug. As a cosmetic ingredient it needs no FDA approval, which is why it appears freely in serums.^[25] For pharmacies that compound it on prescription, the status changed twice in 2026, and it now depends on the route.^[1]

The coming meeting will also cover LL-37, dihexa, Melanotan II and PEG-MGF.^[4] An advisory vote would not settle anything by itself: FDA adds substances to the bulks list through notice-and-comment rulemaking.^[2] Our peptide legal-status guide covers the other peptides on these lists, and 503A vs 503B pharmacies explains the two compounding channels.

Why GHK-Cu shows up next to your GLP-1

Of the 153 telehealth sellers in our register with a structured peptide menu, 32 list GHK-Cu, and 29 of those also publish semaglutide or tirzepatide prices. For someone losing weight, the obvious appeal is skin and hair.

The hair shedding is real, but it usually has a known cause. On these drugs it mostly follows rapid weight loss, as a pattern called telogen effluvium, and in most cases it stops on its own; our review of GLP-1 hair loss covers the labels and studies. That matters here because shedding that would have stopped anyway can make any add-on look like it worked. No trial has tested GHK-Cu in people losing weight on a GLP-1, by any route. The same mismatch between what sells and what has trials runs through the whole peptide add-on menu; our peptide trial review ranks the rest.

If a clinic offers GHK-Cu, it is worth asking:

1. Is this topical or injectable? The two have different evidence and, since May 2026, different FDA status.
2. Which pharmacy makes it, and under what authority? For an injection, ask how the pharmacy squares it with FDA’s exclusion of the injectable route from Category 1.
3. What human evidence supports this use? For hair or anti-aging injections, the honest answer is none yet.
4. Does my prescriber know? Whoever prescribes your GLP-1 should know about anything else you inject, and about any liver or copper-related history.